These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 10182705)

  • 61. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs.
    Patsner B
    Food Drug Law J; 2008; 63(2):459-91. PubMed ID: 18561473
    [No Abstract]   [Full Text] [Related]  

  • 62. Procedures for disclosure or production of information under the Freedom of Information Act; amendments--Consumer Product Safety Commission. Final Rule.
    Fed Regist; 1997 Sep; 62(169):46192-8. PubMed ID: 10169849
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date. Final rule; delay of effective date.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Feb; 69(35):8105-7. PubMed ID: 14997866
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Quality mammography standards--FDA. Proposed rule.
    Fed Regist; 1998 Nov; 63(214):59750-1. PubMed ID: 10187387
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Lohr decision: FDA perspective and position.
    Porter MJ
    Food Drug Law J; 1997; 52(1):7-11. PubMed ID: 10346705
    [No Abstract]   [Full Text] [Related]  

  • 66. Support for the revocation of general safety test regulations in biologics license applications.
    Evans DM; Thorn JM; Arch-Douglas K; Sperry JB; Thompson B; Davis HL; McCluskie MJ
    Biologicals; 2016 May; 44(3):178-81. PubMed ID: 26996102
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The ability of current biologics law to accommodate emerging technologies.
    Carter MJ
    Food Drug Law J; 1996; 51(3):375-80. PubMed ID: 11797714
    [No Abstract]   [Full Text] [Related]  

  • 68. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [State surveillance and control of food quality and safety in USA].
    Berman VA
    Vopr Pitan; 2003; 72(2):22-7. PubMed ID: 12924205
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A strategic road map to filing a Biologics License Application for a pluripotent stem cell derived therapeutic product.
    Creasey AA; Stacey G; Bharti K; Sato Y; Lubiniecki A
    Biologicals; 2019 May; 59():68-71. PubMed ID: 31053443
    [No Abstract]   [Full Text] [Related]  

  • 71. Beverages: bottled water. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Mar; 68(41):9873-82. PubMed ID: 12625359
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Toys and confectionery--a legally hazardous combination?
    Eldred JS; Pape SM
    Food Drug Law J; 1998; 53(1):1-8. PubMed ID: 11795326
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Human drugs and biologics; determination that informed consent is NOT feasible or is contrary to the best interests of recipients; revocation of 1990 interim final rule; establishment of new interim final rule. Food and Drug Administration, HHS. Interim final rule; opportunity for public comment.
    Fed Regist; 1999 Oct; 64(192):54180-9. PubMed ID: 11010702
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Biological technical amendment--FDA. Final rule; technical amendment.
    Fed Regist; 1992 Apr; 57(64):11263. PubMed ID: 10118456
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; inspection and enforcement. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Nov; 69(226):68611-88. PubMed ID: 15562555
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Regulating recombinant DNA biologics.
    Crouch ML
    Arzneimittelforschung; 1988 Jul; 38(7):947-9. PubMed ID: 3207440
    [TBL] [Abstract][Full Text] [Related]  

  • 77. New Advantage 24 contraceptive gel claims 24-hour effectiveness. But proposed FDA rule could put N-9 products to the test.
    Contracept Technol Update; 1995 Apr; 16(4):45-9. PubMed ID: 12347026
    [TBL] [Abstract][Full Text] [Related]  

  • 78. "Guidance for industry: content and format of chemistry, manufacturing and controls information and establishment description information for a biological in vitro diagnostic product;" availability. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 Mar; 64(44):11023-4. PubMed ID: 10557623
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Beverages: bottled water. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Jun; 70(110):33694-701. PubMed ID: 15945150
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Revision to requirements for licensed Anti-Human Globulin and Blood Grouping Reagents. Food and Drug Administration, HHS. Direct final rule.
    Fed Regist; 2000 Dec; 65(239):77497-9. PubMed ID: 11503726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.